Hikma Pharmaceuticals

-13.54%

More reviews (1)

Live  

Hikma Pharmaceuticals is a global pharmaceutical company headquartered in London, United Kingdom. It was founded in 1978 in Amman, Jordan and has since expanded its operations to over 50 countries, with a strong presence in the Middle East, North Africa, and the United States.
Hikma is a leading company in generic and branded pharmaceuticals, serving patients in a wide range of therapeutic areas including respiratory, oncology, infectious diseases, and cardiovascular diseases. The company also has a portfolio of over 1000 branded products, including over-the-counter medications, Hikma-branded generics, and specialty, injectable, and biosimilar products.
Hikma is committed to providing affordable and high-quality medications to people around the world. The company's mission is to help people live better and healthier lives by providing essential medicines and healthcare products.
Hikma has a strong focus on research and development, investing a significant portion of its revenue into developing new products and improving existing ones. The company also works closely with healthcare professionals and patients to understand their needs and develop innovative solutions.
Hikma is also dedicated to sustainability and ethical business practices. The company has implemented numerous initiatives to reduce its environmental impact and ensure responsible sourcing and manufacturing processes.
Overall, Hikma Pharmaceuticals is a well-respected and established global pharmaceutical company with a strong commitment to improving global health and access to affordable medicines.

Hikma Pharmaceuticals is a company that makes medicine to help people feel better when they are sick. They create a variety of medicines, including things like pills, injections, and even liquids that can help treat different health problems.
Hikma makes money by selling these medicines to hospitals, pharmacies, and doctors, who then provide them to patients. When people buy the medicines, Hikma earns money from those sales.
One reason Hikma is successful is that they produce medicines that are in high demand. Many people need medicines for different illnesses, and Hikma helps provide those solutions. They also focus on making high-quality products, which means their medicines are safe and effective.
In the future, Hikma is likely to keep being successful because they are always looking for new ways to help people and new medicines to develop. They are also good at making their products in a way that is both efficient and cost-effective, which can help keep prices lower for customers. Plus, as more people around the world need healthcare, companies like Hikma that provide essential medicines will continue to be important.

MS4gUmljaC BIaXN0b3J5 IGFuZCBFeH BlcmllbmNl OiBIaWttYS BQaGFybWFj ZXV0aWNhbH MgaGFzIGJl ZW4gaW4gb3 BlcmF0aW9u IGZvciBvdm VyIDQwIHll YXJzIGFuZC BoYXMgZ3Jv d24gaW50by BhIGxlYWRp bmcgZ2xvYm FsIHBoYXJt YWNldXRpY2 FsIGNvbXBh bnkgd2l0aC BhIHByb3Zl biB0cmFjay ByZWNvcmQg b2Ygc3VjY2 Vzcy48YnI+ Mi4gRGl2ZX JzaWZpZWQg UHJvZHVjdC BQb3J0Zm9s aW86IFRoZS Bjb21wYW55 IG9mZmVycy BhIGRpdmVy c2UgcmFuZ2 Ugb2YgYnJh bmRlZCBhbm QgZ2VuZXJp YyBtZWRpY2 luZXMsIGFz IHdlbGwgYX MgaW5qZWN0 YWJsZSBhbm QgcmVzcGly YXRvcnkgcH JvZHVjdHMu PGJyPjMuIF N0cm9uZyBH bG9iYWwgUH Jlc2VuY2U6 IEhpa21hIG hhcyBhIHN0 cm9uZyBnbG 9iYWwgcHJl c2VuY2UsIH dpdGggb3Bl cmF0aW9ucy BpbiBvdmVy IDUwIGNvdW 50cmllcyBh bmQgYSBwcm VzZW5jZSBp biBlbWVyZ2 luZyBtYXJr ZXRzLCBtYW tpbmcgaXQg b25lIG9mIH RoZSBtb3N0 IGdlb2dyYX BoaWNhbGx5 IGRpdmVyc2 lmaWVkIHBo YXJtYWNldX RpY2FsIGNv bXBhbmllcy 48YnI+NC4g Rm9jdXMgb2 4gSGlnaC1R dWFsaXR5IG FuZCBBZmZv cmRhYmxlIE 1lZGljaW5l czogSGlrbW EgaXMgY29t bWl0dGVkIH RvIHByb3Zp ZGluZyBoaW doLXF1YWxp dHksIGFmZm 9yZGFibGUg bWVkaWNpbm VzIHRvIGlt cHJvdmUgcG F0aWVudHMn IGxpdmVzIG FuZCBtZWV0 IHRoZWlyIG hlYWx0aGNh cmUgbmVlZH MuPGJyPjUu IEtleSBQYX J0bmVyc2hp cHMgYW5kIE NvbGxhYm9y YXRpb25zOi BIaWttYSBo YXMgZXN0YW JsaXNoZWQg c3Ryb25nIH BhcnRuZXJz aGlwcyB3aX RoIGdsb2Jh bCBwaGFybW FjZXV0aWNh bCBjb21wYW 5pZXMsIGhl YWx0aGNhcm Ugb3JnYW5p emF0aW9ucy wgYW5kIGxv Y2FsIGdvdm Vybm1lbnRz IHRvIGV4cG FuZCBpdHMg cmVhY2ggYW 5kIGRlbGl2 ZXIgaXRzIH Byb2R1Y3Rz IHRvIG1vcm UgcGF0aWVu dHMgd29ybG R3aWRlLjxi cj42LiBFbX BoYXNpcyBv biBSZXNlYX JjaCBhbmQg RGV2ZWxvcG 1lbnQ6IFRo ZSBjb21wYW 55IGludmVz dHMgaGVhdm lseSBpbiBy ZXNlYXJjaC BhbmQgZGV2 ZWxvcG1lbn QgdG8gZGlz Y292ZXIgYW 5kIGRldmVs b3AgbmV3IG 1lZGljaW5l cyBhbmQgaW 1wcm92ZSBl eGlzdGluZy BvbmVzLjxi cj43LiBTdH JvbmcgRmlu YW5jaWFsIF BlcmZvcm1h bmNlOiBIaW ttYSBoYXMg YSBzb2xpZC BmaW5hbmNp YWwgdHJhY2 sgcmVjb3Jk IHdpdGggY2 9uc2lzdGVu dCByZXZlbn VlIGFuZCBw cm9maXRhYm lsaXR5IGdy b3d0aCwgZG Vtb25zdHJh dGluZyBpdH MgYWJpbGl0 eSB0byBuYX ZpZ2F0ZSBt YXJrZXQgY2 hhbGxlbmdl cyBhbmQgZG VsaXZlciBz dHJvbmcgcm V0dXJucyB0 byBzaGFyZW hvbGRlcnMu PGJyPjguIF NvdW5kIENv cnBvcmF0ZS BTb2NpYWwg UmVzcG9uc2 liaWxpdHkg KENTUikgUH JhY3RpY2Vz OiBUaGUgY2 9tcGFueSBp cyBjb21taX R0ZWQgdG8g bWFraW5nIG EgcG9zaXRp dmUgaW1wYW N0IG9uIHNv Y2lldHkgdG hyb3VnaCB2 YXJpb3VzIE NTUiBpbml0 aWF0aXZlcy wgaW5jbHVk aW5nIHByb2 1vdGluZyBh Y2Nlc3MgdG 8gaGVhbHRo Y2FyZSwgc3 VwcG9ydGlu ZyBlZHVjYX Rpb24gYW5k IGVudmlyb2 5tZW50YWwg c3VzdGFpbm FiaWxpdHku PGJyPjkuIE F3YXJkLVdp bm5pbmcgQ2 9tcGFueTog SGlrbWEgaG FzIHJlY2Vp dmVkIHNldm VyYWwgYXdh cmRzIGFuZC ByZWNvZ25p dGlvbiBmb3 IgaXRzIG9w ZXJhdGlvbn MsIHByb2R1 Y3RzLCBhbm QgY29ycG9y YXRlIHByYW N0aWNlcywg aW5jbHVkaW 5nIGJlaW5n IG5hbWVkIG 9uZSBvZiB0 aGUgbW9zdC BldGhpY2Fs IGNvbXBhbm llcyBpbiB0 aGUgd29ybG QgYnkgdGhl IEV0aGlzcG hlcmUgSW5z dGl0dXRlLj xicj4xMC4g Q3VsdHVyZS BvZiBJbm5v dmF0aW9uIG FuZCBFeGNl bGxlbmNlOi BIaWttYSBo YXMgZXN0YW JsaXNoZWQg YSBjdWx0dX JlIG9mIGlu bm92YXRpb2 4gYW5kIGV4 Y2VsbGVuY2 UgdGhhdCBk cml2ZXMgaX RzIHN1Y2Nl c3MgYW5kIG FsbG93cyBp dCB0byBhZG FwdCB0byBj aGFuZ2luZy BtYXJrZXQg ZHluYW1pY3 MgYW5kIG1l ZXQgdGhlIG V2b2x2aW5n IGhlYWx0aG NhcmUgbmVl ZHMgb2YgcG F0aWVudHMu

VGhlIGJ1c2 luZXNzIG1v ZGVsIG9mIE hpa21hIFBo YXJtYWNldX RpY2FscyBp cyBiYXNlZC BvbiB0aGUg ZGV2ZWxvcG 1lbnQsIG1h bnVmYWN0dX JpbmcsIGFu ZCBtYXJrZX Rpbmcgb2Yg YSB3aWRlIH JhbmdlIG9m IGdlbmVyaW MsIGJyYW5k ZWQsIGFuZC Bpbi1saWNl bnNlZCBwaG FybWFjZXV0 aWNhbCBwcm 9kdWN0cy4g VGhlIGNvbX Bhbnkgb3Bl cmF0ZXMgcH JpbWFyaWx5 IGluIHRoZS BNRU5BIHJl Z2lvbiwgdG hlIFVuaXRl ZCBTdGF0ZX MsIGFuZCBF dXJvcGUsIG ZvY3VzaW5n IG9uIHByb3 ZpZGluZyBh ZmZvcmRhYm xlIGFuZCBo aWdoLXF1YW xpdHkgbWVk aWNpbmVzIH RvIHBhdGll bnRzIGluIH RoZXNlIG1h cmtldHMuPG JyPkhpa21h J3MgYnVzaW 5lc3MgbW9k ZWwgaXMgZG l2aWRlZCBp bnRvIHRocm VlIG1haW4g c2VnbWVudH M6PGJyPjEu IEJyYW5kZW QgUGhhcm1h Y2V1dGljYW xzOiBUaGlz IHNlZ21lbn QgaW5jbHVk ZXMgdGhlIH Jlc2VhcmNo LCBkZXZlbG 9wbWVudCwg YW5kIG1hcm tldGluZyBv ZiBpbm5vdm F0aXZlIGJy YW5kZWQgbW VkaWNpbmVz LiBIaWttYS dzIGJyYW5k ZWQgcG9ydG ZvbGlvIGZv Y3VzZXMgb2 4gdGhlcmFw ZXV0aWMgYX JlYXMgc3Vj aCBhcyBvbm NvbG9neSwg Y2FyZGlvdm FzY3VsYXIs IHJlc3Bpcm F0b3J5LCBh bmQgbmV1cm 9sb2d5LCBh bW9uZyBvdG hlcnMuPGJy PjIuIEdlbm VyaWMgUGhh cm1hY2V1dG ljYWxzOiBU aGlzIHNlZ2 1lbnQgaW5j bHVkZXMgdG hlIGRldmVs b3BtZW50LC BtYW51ZmFj dHVyZSwgYW 5kIGRpc3Ry aWJ1dGlvbi BvZiBoaWdo LXF1YWxpdH kgZ2VuZXJp YyBkcnVncy 4gSGlrbWEg b2ZmZXJzIG EgYnJvYWQg cG9ydGZvbG lvIG9mIGdl bmVyaWMgcH JvZHVjdHMg aW4gdmFyaW 91cyB0aGVy YXBldXRpYy BhcmVhcywg aW5jbHVkaW 5nIG9uY29s b2d5LCBjYX JkaW92YXNj dWxhciwgYW 5kIGNlbnRy YWwgbmVydm 91cyBzeXN0 ZW0uPGJyPj MuIEluamVj dGFibGVzOi BIaWttYSBp cyBvbmUgb2 YgdGhlIHdv cmxkJ3MgbG FyZ2VzdCBt YW51ZmFjdH VyZXJzIG9m IGdlbmVyaW MgaW5qZWN0 YWJsZSBkcn Vncy4gSXQg c3BlY2lhbG l6ZXMgaW4g Y29tcGxleC wgc3Rlcmls ZSBpbmplY3 RhYmxlIHBy b2R1Y3RzLC BpbmNsdWRp bmcgb25jb2 xvZ3ksIGNy aXRpY2FsIG NhcmUsIGFu ZCBhbnRpLW luZmVjdGl2 ZXMuPGJyPk luIGFkZGl0 aW9uIHRvIH RoZXNlIHNl Z21lbnRzLC BIaWttYSBh bHNvIGhhcy BhIHN0cm9u ZyBmb2N1cy BvbiByZXNl YXJjaCBhbm QgZGV2ZWxv cG1lbnQsIH dpdGggb25n b2luZyBpbn Zlc3RtZW50 IGluIG5ldy Bwcm9kdWN0 IGRldmVsb3 BtZW50IGFu ZCBlbmhhbm NpbmcgaXRz IGV4aXN0aW 5nIHByb2R1 Y3QgcG9ydG ZvbGlvLiBU aGUgY29tcG FueSBhbHNv IGxldmVyYW dlcyBzdHJh dGVnaWMgcG FydG5lcnNo aXBzIGFuZC Bjb2xsYWJv cmF0aW9ucy B0byBleHBh bmQgaXRzIH Byb2R1Y3Qg b2ZmZXJpbm cgYW5kIGdl b2dyYXBoaW NhbCBwcmVz ZW5jZS48Yn I+T3ZlcmFs bCwgSGlrbW EncyBidXNp bmVzcyBtb2 RlbCBpcyBk cml2ZW4gYn kgaXRzIGNv bW1pdG1lbn QgdG8gcHJv dmlkaW5nIG hpZ2gtcXVh bGl0eSwgYW Zmb3JkYWJs ZSBtZWRpY2 luZXMgdG8g cGF0aWVudH MsIHN1cHBv cnRlZCBieS BhIHJvYnVz dCByZXNlYX JjaCBhbmQg ZGV2ZWxvcG 1lbnQgcGlw ZWxpbmUgYW 5kIGEgZ2xv YmFsIHByZX NlbmNlLg==

AI has the potential to impact Hikma Pharmaceuticals in several ways, but the extent of the threat depends on various factors.
1. Substitution: AI technologies could provide alternative solutions for medication development, patient care, or drug delivery. For example, AI-powered tools can help in drug discovery, potentially speeding up the process and reducing costs. If these alternatives prove to be more efficient or cost-effective, they could pose a substitution threat to Hikma’s offerings.
2. Disintermediation: AI could streamline supply chains and reduce the need for intermediaries in the pharmaceutical distribution process. This may impact Hikma’s traditional distribution channels, making it essential for the company to adapt its business model to maintain its competitive edge.
3. Margin Pressure: With the use of AI in drug manufacturing and development, companies can achieve efficiencies that lower production costs. As competitors adopt these technologies, Hikma might face margin pressure if it cannot keep pace with the cost reductions and efficiency gains, forcing it to either reduce prices or invest heavily in AI technologies.
In summary, while AI presents opportunities for enhancing drug development and operational efficiency, it also poses a material threat through substitution, disintermediation, and potential margin pressure. Hikma Pharmaceuticals will need to proactively leverage AI in its strategies to mitigate these risks and sustain its competitive positioning.

The sensitivity of Hikma Pharmaceuticals’ earnings, cash flow, and valuation to changes in interest rates can be analyzed from several perspectives.
1. Earnings Sensitivity: Changes in interest rates can affect Hikma’s cost of borrowing. If interest rates rise, the company’s interest expenses may increase, directly impacting net income. Higher rates could also slow down overall economic growth, potentially leading to lower demand for pharmaceuticals, which could further affect earnings.
2. Cash Flow Sensitivity: Interest rates influence cash flow primarily through the cost of debt. Increased interest rates can lead to higher debt servicing costs, reducing free cash flow available for operations, investment, or dividends. Conversely, lower interest rates can enhance cash flow by decreasing these costs. The company’s ability to generate cash is also tied to its market environment, where rate changes can affect consumer behavior and healthcare spending.
3. Valuation Sensitivity: The valuation of Hikma Pharmaceuticals, like many companies, is affected by changes in interest rates due to their impact on the discount rate used in financial models. Higher interest rates typically increase the discount rate, which can lower the present value of future cash flows, leading to a reduced valuation. In contrast, lower interest rates can increase valuations by reducing the discount rate.
Overall, the sensitivity of Hikma Pharmaceuticals’ financial metrics to changes in interest rates is moderate, influenced by borrowing costs, overall economic conditions, and investor perceptions of risk and return. The effects are interconnected, and sustained fluctuations in interest rates can have cascading impacts on the company’s financial health and market valuation.

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvYV BMZnRaWDFH WFlaRWlvbV BNMEoud2Vi cCIgYWx0PS JIaWttYSBQ aGFybWFjZX V0aWNhbHMi IHRpdGxlPS JIaWttYSBQ aGFybWFjZX V0aWNhbHMi ICBjbGFzcz 0iaW1nLWZs dWlkIiBoZW lnaHQ9OTAg d2lkdGg9OT AgbG9hZGlu Zz0nbGF6eS cgc3R5bGU9 J2JvcmRlci 1yYWRpdXM6 IDZweDsnPg oKICAgICAg ICAgICAgIC AgICAgICA8 ZGl2IHN0eW xlPSdmbGV4 OiAxOyB0ZX h0LWFsaWdu OiBjZW50ZX I7IG1hcmdp bi1sZWZ0Oi A1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgPHAgc3R5 bGU9J2Zvbn Qtc2l6ZTog MjZweDsgY2 9sb3I6ICMz MzM7IG1hcm dpbi1ib3R0 b206IDE1cH g7Jz4KICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIPCfk4gg V2FudCB0by ByZWFkIG1v cmUgYWJvdX QgSGlrbWEg UGhhcm1hY2 V1dGljYWxz PwogICAgIC AgICAgICAg ICAgICAgIC AgICA8L3A+ CgogICAgIC AgICAgICAg ICAgICAgIC AgICA8YSBo cmVmPSdpbm RleC5waHA/ cGFnZT1zaW dudXAnIHN0 eWxlPScKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGJhY2 tncm91bmQt Y29sb3I6IC MwMDdCRkY7 CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBj b2xvcjogI2 ZmZjsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH ggMjBweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIGJv cmRlci1yYW RpdXM6IDVw eDsKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IHRleHQtZG Vjb3JhdGlv bjogbm9uZT sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG ZvbnQtd2Vp Z2h0OiBib2 xkOwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgbWFyZ2lu LXJpZ2h0Oi AxMHB4Owog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgdHJh bnNpdGlvbj ogYmFja2dy b3VuZC1jb2 xvciAwLjNz IGVhc2U7Jw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgb2 5tb3VzZW92 ZXI9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA1Nm IzIicKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIG9ubW91 c2VvdXQ9J3 RoaXMuc3R5 bGUuYmFja2 dyb3VuZENv bG9yPSIjMD A3QkZGIic+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBT aWduIHVwIG ZvciBmcmVl CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDwvYT4K CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDxzcGFu IHN0eWxlPS dtYXJnaW46 IDAgOHB4Oy Bjb2xvcjog IzU1NTsnPm 9yPC9zcGFu PgoKICAgIC AgICAgICAg ICAgICAgIC AgICAgPGEg aHJlZj0naW 5kZXgucGhw P3BhZ2U9bG 9naW4nIHN0 eWxlPScKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGNvbG 9yOiAjMDA3 QkZGOwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgdGV4dC 1kZWNvcmF0 aW9uOiB1bm RlcmxpbmU7 CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBm b250LXdlaW dodDogNTAw Oyc+CiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICBsb2cgaW 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgPC9hPg oKCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDxwIH N0eWxlPSdt YXJnaW4tdG 9wOiAxNXB4 OyBmb250LX NpemU6IDEz cHg7IGZvbn Qtd2VpZ2h0 OiBib2xkOy Bjb2xvcjog I2QzMmYyZj snPgogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC Ag4pyN77iP IFNpZ24gdX AgdG8gZ2V0 IDxpPiJUaG UgQ2hlY2ts aXN0IFZhbH VlIEludmVz dG9yIOKAlC BBIFNtYXJ0 ZXIgV2F5IH RvIFBpY2sg U3RvY2tzIj wvaT4gZm9y IGZyZWUKIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9wPgoKIC AgICAgICAg ICAgICAgIC AgICAgICAg PCEtLQogIC AgICAgICAg ICAgICAgIC AgICAgICA8 ZGl2IHN0eW xlPSdtYXJn aW4tdG9wOi AxMnB4OyBm b250LXNpem U6IDEzcHg7 IGNvbG9yOi AjNDQ0Oyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBT aWduIHVwIG 5vdyBhbmQg Z2V0IG91ci BmcmVlIGVC b29rIAogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgPGI+VG hlIENoZWNr bGlzdCBWYW x1ZSBJbnZl c3RvciDigJ QgQSBTbWFy dGVyIFdheS B0byBQaWNr IFN0b2Nrcz wvYj4KICAg ICAgICAgIC AgICAgICAg ICAgICAgPC 9kaXY+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC 0tPgogICAg ICAgICAgIC AgICAgICAg ICAgICA8IS 0tCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDxkaX Ygc3R5bGU9 J21hcmdpbi 10b3A6IDE2 cHg7IGZvbn Qtc2l6ZTog MTRweDsgY2 9sb3I6ICM0 NDQ7IGZvbn QtZmFtaWx5 OiAtYXBwbG Utc3lzdGVt LCBCbGlua0 1hY1N5c3Rl bUZvbnQsIF NlZ29lIFVJ LCBSb2JvdG 8sIEhlbHZl dGljYSBOZX VlLCBzYW5z LXNlcmlmOy BsaW5lLWhl aWdodDogMS 42Oyc+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBIYXZl IHlvdSBoZW FyZCBhYm91 dCBvdXIgc2 hvcnQgPHN0 cm9uZyBzdH lsZT0nZm9u dC13ZWlnaH Q6IDYwMDsn PkRhaWx5IF ZpZGVvIE5l d3NsZXR0ZX I8L3N0cm9u Zz4/CiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICA8YSBocm VmPSdodHRw czovL3d3dy 5pbnNpZ2h0 ZnVsdmFsdW UuY29tL25l d3NsZXR0ZX IucGhwJyB0 YXJnZXQ9J1 9ibGFuaycg c3R5bGU9J2 NvbG9yOiAj MDA3QkZGOy B0ZXh0LWRl Y29yYXRpb2 46IG5vbmU7 IGZvbnQtd2 VpZ2h0OiA1 MDA7IG1hcm dpbi1sZWZ0 OiA2cHg7Jz 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBGaW5k IG91dCBtb3 JlCiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC A8L2E+CiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvZGl2Pgog ICAgICAgIC AgICAgICAg ICAgICAgIC AtLT4KICAg ICAgICAgIC AgICAgICAg ICA8L2Rpdj 4KICAgICAg ICAgICAgIC AgIDwvZGl2 PgogICAgIC AgICAgICA8 L2Rpdj4KIC AgICAgICAg ICAgCiAgIC AgICAgCiAg ICAgICAgPH NwYW4gY2xh c3M9J2JsdX JyZWQtdGV4 dCc+CiAgIC AgICAgICAg IE1TNGdTR2 xyYlcgRWdV R2hoY20xaC BZMlYxZEds allXIHh6SU hkaGN5Qm0g YjNWdVpHVm tJRyBsdUlE RTVOemdnIG FXNGdRVzF0 WVcgNHNJRX B2Y21SaCBi aUJpZVNCVF lXIDFwYUNC RVlYSjMgWV hwaGFDd2dk MiBodklISm xiV0ZwIGJu TWdkR2hsSU UgaHZibTl5 WVhKNSBJRU 5vWVdseWJX IEZ1SUc5bU lIUm8gWlNC amIyMXdZVy A1NUxqeGlj ajR5IExpQl VhR1VnYm0g RnRaU0JJYV d0dCBZU0Fv WVd4emJ5IE J6Y0dWc2JH VmsgSUVoaG EybHRZVyBn cElHbHpJR0 Z1IElFRnlZ V0pwWXkgQj NiM0prSUcx bCBZVzVwYm 1jZ2QyIGx6 Wkc5dElHOX kgSUd0dWIz ZHNaVyBSbl pTNDhZbkkr IE15NGdTR2 xyYlcgRWdV R2hoY20xaC BZMlYxZEds allXIHh6SU hOMFlYSjAg WldRZ1lYTW dZUyBCemJX RnNiQ0JtIF lXMXBiSGtn WW4gVnphVz VsYzNNcyBJ SGRwZEdnZ2 FuIFZ6ZENB eE5pQmwgYl hCc2IzbGxa WCBNZ1lXNW tJR0VnIGMy bHVaMnhsSU ggQnliMlIx WTNRdSBQR0 p5UGpRdUlG IFJvWlNCam IyMXcgWVc1 NUlHVjRjRy BGdVpHVmtJ SEpoIGNHbG tiSGtzSUcg RnVaQ0JpZV NBeCBPVGsy TENCcGRDIE JvWVdRZ1lt VmogYjIxbE lIUm9aUyBC c1lYSm5aWE 4wIElIQm9Z WEp0WVcgTm xkWFJwWTJG cyBJRzFoYm 5WbVlXIE4w ZFhKbGNpQn AgYmlCMGFH VWdUVyBsa1 pHeGxJRVZo IGMzUWdZVz VrSUUgNXZj blJvSUVGbS BjbWxqWVM0 OFluIEkrTl M0Z1NXNGcg TVRrNU5pd2 dTRyBscmJX RWdiM0JsIG JtVmtJR2ww Y3kgQm1hWE p6ZENCcCBi blJsY201aG RHIGx2Ym1G c0lIQnkgYj JSMVkzUnBi MiA0Z1ptRm phV3hwIGRI a2dhVzRnVU cgOXlkSFZu WVd3cyBJR1 p2Ykd4dmQy IFZrSUdKNU lHWmggWTJs c2FYUnBaWC BNZ2FXNGdT WFJoIGJIa2 dZVzVrSUgg Um9aU0JWYm 1sMCBaV1Fn VTNSaGRHIF Z6TGp4aWNq NDIgTGlCSm JpQXlNRCBB MUxDQklhV3 R0IFlTQlFh R0Z5YlcgRm paWFYwYVdO aCBiSE1nWW 1WallXIDFs SUhSb1pTQm 0gYVhKemRD Qk5hVyBSa2 JHVWdSV0Z6 IGRHVnliaU JqYjIgMXdZ VzU1SUhSdi BJR0psSUd4 cGMzIFJsWk NCdmJpQjAg YUdVZ1RHOX VaRyA5dUlG TjBiMk5yIE lFVjRZMmho Ym0gZGxMan hpY2o0MyBM aUJJYVd0dF lTIEJvWVhN Z1lTQnogZE hKdmJtY2da bSA5amRYTW diMjRnIGNt VnpaV0Z5WT IgZ2dZVzVr SUdSbCBkbV ZzYjNCdFpX IDUwTENCM2 FYUm8gSUc5 MlpYSWdPRC BBd0lITmph V1Z1IGRHbH pkSE1nWVcg NWtJSEpsYz JWaCBjbU5v WlhKeklIIG R2Y210cGJt Y2cgYVc0Z2 RHaGxhWCBJ Z1VpWkVJR0 5sIGJuUmxj bk1nWVggSn ZkVzVrSUhS byBaU0IzYj NKc1pDIDQ4 WW5JK09DNG cgVkdobElH TnZiWCBCaG Jua2dhR0Z6 IElHRWdjRz l5ZEcgWnZi R2x2SUc5bS BJRzkyWlhJ Z09EIEF3SU hCeWIyUjEg WTNSekxDQn lZVyA1bmFX NW5JR1p5IG IyMGdZbkpo Ym0gUmxaQ0 JuWlc1bCBj bWxqY3lCMG J5IEJpY21G dVpHVmsgSU dGdVpDQnpj RyBWamFXRn NhWHBsIFpD QndjbTlrZF cgTjBjeTQ4 WW5JKyBPUz RnU0dscmJX IEVnYVhNZ2 RHaGwgSUd4 aGNtZGxjMy BRZ2NHaGhj bTFoIFkyVj FkR2xqWVcg d2dZMjl0Y0 dGdSBlU0Jw YmlCMGFHIF VnVFVWT1FT QnkgWldkcG IyNHNJSCBk cGRHZ2diM0 JsIGNtRjBh Vzl1Y3kgQn BiaUJ2ZG1W eSBJRFV3SU dOdmRXIDUw Y21sbGN5ND ggWW5JK01U QXVJRiBSb1 pTQmpiMjF3 IFlXNTVJR2 hoY3kgQmhJ SE4wY205dS BaeUJqYjIx dGFYIFJ0Wl c1MElIUnYg SUhOMWMzUm hhVyA1aFlt bHNhWFI1IE lHRnVaQ0Jv WVggTWdZbV ZsYmlCeSBa V052WjI1cG VtIFZrSUda dmNpQnAgZE hNZ1pXWm1i MyBKMGN5Qn BiaUJ5IFpX UjFZMmx1Wn kgQnBkSE1n Wlc1MiBhWE p2Ym0xbGJu IFJoYkNCcG JYQmggWTNR Z1lXNWtJSC BCeWIyMXZk R2x1IFp5Qn piMk5wWVcg d2djbVZ6Y0 c5dSBjMmxp YVd4cGRIIG t1CiAgICAg ICAgPC9zcG FuPgogICAg ICAgIAogIC AgICAgIA==